Oxford, UK – 15 October 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be hosting booths at two key US cytogenetics meetings over the next few weeks. The first is the Association for Molecular Pathology (AMP) Annual Meeting on Genomic Medicine 2012 to be held in Long Beach, CA (25-27 October), and the second the American Society of Human Genetics Annual Meeting 2012 in San Francisco, CA (6-10 November). Pathologists and cytogeneticists can visit the OGT booths to discuss the challenges currently facing molecular pathology with the company’s experts. Perhaps most excitingly, OGT will be making a major announcement at the ASHG meeting, full details of which will be made publicly available after the meeting.
OGT has significant expertise in the area of cytogenetic analysis and has recently released a new series of microarrays specifically enhanced for investigating the genetic basis of cancer and other congenital diseases, including the CytoSure™ Haematological Cancer +SNP Array and the CytoSure ISCA +SNP Array, with enhanced SNP resolution. By combining both aCGH and SNP probes, these arrays make it is possible to carry out the accurate and cost-effective detection of both copy number changes and loss of heterozygosity, all in a single experiment. Analysis is further optimised via seamless integration with OGT’s powerful CytoSure Interpret Software, which rapidly and intuitively guides researchers to the important genetic variations in their samples, without the need for extensive bioinformatics expertise.
To request a personal demonstration of CytoSure Interpret Software during either meeting, please contact email@example.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Diagnostic Biomarkers: Utilising proprietary next generation technologies, OGT is building a rich patent-protected portfolio of promising biomarkers for early-stage cancer and autoimmune disease detection. The biomarker pipeline includes advanced programmes in colorectal cancer, prostate cancer and pancreatic cancer plus the autoimmune disease systemic lupus erythematosus (SLE). OGT is currently assessing partnership opportunities to commercialise these biomarker panels.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.